Literature DB >> 6965483

Dose and serum concentration relationships in cimetidine-associated mental confusion.

B J Kimelblatt, F B Cerra, G Calleri, M J Berg, M A McMillen, J J Schentag.   

Abstract

A patient with severe liver disease and mildly obnormal but stable renal function was given cimetidine on two occasions for gastrointestinal hemorrhage. In each course, dosing was initiated at half the recommended dosage of 600 mg daily, and mental status deteriorated shortly after dosing began. A further dosage decrease to 300 mg daily allowed continuation of cimetidine therapy in absence of mental status alterations. In this patient, mental status changes occurred at lower serum concentrations than we have previously reported. This discrepancy was explained by analysis of cimetidine CSF concentrations, as this patient had abnormally high cimetidine blood to CSF permeability. Although the cause of increased CSF concentrations is unclear, cimetidine-associated mental confusion was dose related and completely reversible upon a decrease in dosage. Patients who develop cimetidine-associated mental status changes and who cannot have treatment stopped may be safely treated by individualizing the dosing rate.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6965483

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  20 in total

Review 1.  Drug-induced cognitive impairment in the elderly.

Authors:  A R Moore; S T O'Keeffe
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

Review 2.  Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

Authors:  J H Lin
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 4.  Gastrointestinal prophylaxis in neurocritical care.

Authors:  Clemens M Schirmer; Joshua Kornbluth; Carl B Heilman; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

Review 5.  Safety of acid-suppressing drugs.

Authors:  R A Smallwood; R G Berlin; N Castagnoli; H P Festen; C J Hawkey; S K Lam; M J Langman; P Lundborg; A Parkinson
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 6.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

7.  Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.

Authors:  R Vinayek; W F Hahne; A R Euler; J A Norton; R T Jensen
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

8.  The comparative efficacy of cimetidine and ranitidine in controlling gastric pH in critically ill patients.

Authors:  S R Reid; C D Bayliff
Journal:  Can Anaesth Soc J       Date:  1986-05

9.  Cimetidine elimination from the cerebrospinal fluid of the rat.

Authors:  M T Whittico; K M Giacomini
Journal:  Pharm Res       Date:  1988-10       Impact factor: 4.200

Review 10.  Clinical pharmacokinetics of cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.